This HTML5 document contains 96 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1159/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q41705039
rdf:type
wikibase:Item
schema:description
επιστημονικό άρθρο 1998年論文 vitskapeleg artikkel tieteellinen artikkeli wissenschaftlicher Artikel 1998年論文 научная статья bài báo khoa học مقالة علمية نشرت في يناير 1998 artículo científico publicado en 1998 1998年論文 articolo scientifico artikulong pang-agham vitenskapelig artikkel videnskabelig artikel мақолаи илмӣ научни чланак bilimsel makale scienca artikolo teaduslik artikkel scientific article published on January 1998 artigo científico 1998年论文 artikel ilmiah 1998年论文 artykuł naukowy 1998年論文 1998년 논문 научна статия 1998年论文 наукова стаття, опублікована в січні 1998 1998年の論文 artikull shkencor scientific article published on January 1998 1998年论文 სამეცნიერო სტატია vedecký článok wetenschappelijk artikel artigo científico vetenskaplig artikel บทความทางวิทยาศาสตร์ article scientific scientific article published on January 1998 vědecký článek מאמר מדעי naučni članak article scientifique artigo científico artículu científicu espublizáu en 1998 1998年论文 articol științific tudományos cikk জানুয়ারি ১৯৯৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 1998 nî lūn-bûn 1998年論文 1998年论文 научни чланак article científic
p:P577
wds:Q41705039-C7C45BAA-D6A2-4936-83E5-94249F01D58B
wdt:P577
1998-01-01T00:00:00Z
p:P407
wds:Q41705039-0EFD88CE-857F-4460-9A95-3D6186087273
wdt:P407
wd:Q1860
p:P2093
wds:Q41705039-1C6D437C-C872-480A-8FF0-76EB82B3EB52 wds:Q41705039-B5957F09-25CC-48F5-AA73-A20FC3329DC2 wds:Q41705039-C16FA5D4-19D8-47C6-B596-BCF7968732F3 wds:Q41705039-B0F23708-7E01-4286-8ED6-79A5599023A8 wds:Q41705039-D443CB9C-07EF-424F-8CED-D5A3EFC71C3B wds:Q41705039-ED60B6D0-EC01-4200-B675-DC7A6D7D8F4A
wdt:P2093
Soloway M Denis L Tyrrell CJ Newling D Channer K Cockshott ID
rdfs:label
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group
skos:prefLabel
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group
schema:name
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group
p:P1476
wds:Q41705039-C34A02E2-8F5E-4F42-AF08-BD791CEC7EF7
wdt:P1476
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group
p:P304
wds:Q41705039-A92702FE-99D1-4B92-A7B3-F54F2C63B468
wdt:P304
39-53
p:P31
wds:Q41705039-2BDADF0E-BF89-4E44-B268-A10D53BFEACE
wdt:P31
wd:Q13442814
p:P698
wds:Q41705039-2B8A09A4-31E1-448A-9605-5338A7351925
wdtn:P698
n11:9471040
wdt:P698
9471040
p:P1433
wds:Q41705039-5A2BA7A8-835C-4495-8065-8C90B051501D
wdt:P1433
wd:Q15763991
p:P433
wds:Q41705039-F6D4BB54-1CDC-4A63-BAE2-F43A4D219119
p:P478
wds:Q41705039-6061250E-D7A3-4DF3-9A27-CFBF5141D8B5
wdt:P433
1
wdt:P478
33
p:P356
wds:Q41705039-26DA3BBE-45B2-480A-8B4D-3FDACEA584B9
wdtn:P356
n10:000019526
wdt:P356
10.1159/000019526